Find a Physician » Medical Practices » Infectious Diseases and HIV Medicine » Research   Search   
 Research & Development Minimize
About Our Research Program
Under the direction of division chief Jeffrey M. Jacobson, M.D., the Division of Infectious Diseases and HIV Medicine is expanding our translational research program, and investigating cutting-edge technologies, vaccines, and therapeutic treatments for the management and prevention of HIV and other infectious diseases. Current and pending research studies involve close collaborations with DUCOM's Department of Microbiology and Immunology, and Department of Emergency Medicine, as well as the Drexel University School of Public Health.

 Lab Research

Michele Kutzler, Ph.D., is currently investigating the development of DNA vaccines, therapeutics to treat Clostidium difficile, and the immune responses of intravenous drug users. In addition, her lab processes specimens from the Division's clinical research studies. See Dr. Kutzler's biosketch.

Clinical Research

These are some of our current clinical studies. Participants who are entered into any of the studies will be compensated for time, travel, and meals. Please contact Sharon Lewis, R.N., at 215-762-3251.
 
DENDRITIC VACCINE STUDY
 
Sponsor: Argos
Purpose: To establish a group of subjects in an anti-HIV medication study for the purposes of making a personalized HIV vaccine
Summary:  Patient's own virus will be mixed with dendritic cells to make a customized vaccine
 
Eligibility Criteria
        HIV-infected men or women
        Age: 18-60
        CD4: over 200
        Viral load: >15,000
     Have been off antirretroviral medications for at least 12 weeks prior to study
 
Exclusion Criteria
        Have had a positive test for Hepatitis C or B
        Have had a positive test for syphilis

  Please contact Sharon Lewis, R.N., at 215-762-3251.

ELITE CONTROLLER STUDY
 
Sponsor: Investigator-initiated with University of Montreal
Purpose: To evaluate patients who have been able to control the progression of HIV for long periods without the use of ART.
Summary: White blood cells, obtained through leukapheresis, will be studied for HIV immune response.
 
Eligibility Criteria
        HIV-infected men or women
        Age: 18-75
        CD4: any
        Viral load: less than 100
        ART-naïve (no history of taking HIV medications)
 
Exclusion Criteria 
        Have had clinical progression to AIDS
        Have a history of taking HIV medications
        Have poor peripheral veins and unable to have leukapheresis
 
Please contact Sharon Lewis, R.N., at 215-762-3251.

 Print   

Philadelphia Health & Education Corporation d/b/a Drexel University College of Medicine is a separate not-for-profit subsidiary of Drexel University.